- Home
- HROW vs ZBH Comparison
HROW vs ZBH Comparison
Compare HROW & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HROW | ZBH |
|---|---|---|
| Founded | 1998 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 18.7B |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | HROW | ZBH |
|---|---|---|
| Price | $47.21 | $91.63 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 8 | 20 |
| Target Price | $68.86 | ★ $107.79 |
| AVG Volume (30 Days) | 524.1K | ★ 2.1M |
| Earning Date | 11-10-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 1.05% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 4.03 |
| Revenue | $250,042,000.00 | ★ $8,010,900,000.00 |
| Revenue This Year | $39.05 | $7.99 |
| Revenue Next Year | $40.48 | $5.20 |
| P/E Ratio | ★ N/A | $22.71 |
| Revenue Growth | ★ 47.83 | 5.47 |
| 52 Week Low | $20.85 | $85.33 |
| 52 Week High | $51.30 | $114.44 |
Technical Indicators
Market Signals| Indicator | HROW | ZBH |
|---|---|---|
| Relative Strength Index (RSI) | 60.58 | 43.05 |
| Support Level | $44.48 | $91.46 |
| Resistance Level | $47.90 | $93.85 |
| Average True Range (ATR) | 2.46 | 2.06 |
| MACD | 0.82 | 0.03 |
| Stochastic Oscillator | 68.13 | 13.51 |
Price Performance
Historical ComparisonAbout HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans. Its operating segments are The Branded segment includes activities of the Company's FDA-approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of branded products; and The ImprimisRx segment represents activities in the Company's ophthalmology-focused pharmaceutical compounding business.
About ZBH Zimmer Biomet Holdings Inc.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.